Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$68.31 USD

68.31
403,799

+0.94 (1.40%)

Updated Sep 18, 2025 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Henry Schein (HSIC) Digital Dentistry Gains, Expands Globally

by Zacks Equity Research

Henry Schein (HSIC) witnesses strength in dental consumable merchandise sales in France, Germany, Austria, Belgium.

Zacks Equity Research

Masimo (MASI) Announces Favorable Study Results on SpHb

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to enhance perioperative transfusion management and post-operative patient outcomes on pediatric patients.

Zacks Equity Research

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strong international performances and favorable 2022 outlook.

Zacks Equity Research

Abbott's (ABT) CGM Device Gets MHLW Nod for Expanded Coverage

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre system will allow diabetics to get the glucose data required to manage their condition without using routine fingersticks.

Zacks Equity Research

Reasons to Retain Intuitive Surgical (ISRG) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Zacks Equity Research

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

Zacks Equity Research

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

by Zacks Equity Research

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.

Zacks Equity Research

Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays

by Zacks Equity Research

According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

Zacks Equity Research

Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research

by Zacks Equity Research

Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.

Zacks Equity Research

Here's Why You Should Invest in Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

Zacks Equity Research

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.

Zacks Equity Research

Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care

by Zacks Equity Research

Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.

Zacks Equity Research

Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair

by Zacks Equity Research

Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.

Zacks Equity Research

Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?

by Zacks Equity Research

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Zacks Equity Research

HSIC vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Zacks Equity Research

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment toward clinical studies. However, limited commercial expertise is a woe.

Zacks Equity Research

Here's Why You Should Retain Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

Zacks Equity Research

Reasons to Add Allscripts (MDRX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.

Zacks Equity Research

Catalent's (CTLT) New Project Completion Expands Global Footprint

by Zacks Equity Research

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.